Long-term Multidomain Clinical Response to Deucravacitinib in SLE: Four-Year Integrated Analyses From a Phase 2 Randomized Study and Its Long-Term Extension (ACR Convergence 2026) - Sep 8, 2026 - Abstract #2213; Pres time: Nov 10, 2026; 10:30 AM - 12:30 PM; Location: WB1&2; In Person; No abstract available
Clinical • P2 data • Inflammatory Arthritis
|
|
Ronald Van Vollenhoven, MD, PhD, MACR
|